98%
921
2 minutes
20
Venous Ulcers (VU) represent 60-80% of all leg ulcers and are the final stage of the disease secondary to venous hypertension or valve insufficiency. Conventional treatment that focuses on its etiological factors continues to be the gold standard; however, 30% of ulcers do not heal with this treatment; thus, it has been seen that the use of growth factor can be used as an adjuvant for this pathology. A literature review was carried out to evaluate the evidence from systematic reviews, meta-analyses, case studies, and quantitative studies that respond to the objective of this analysis review in the different databases with specific inclusion criteria with publications between 2002 and 2022, initially finding the topical application of the factor and later, more recently, the intralesional and perilesional application, the latter being an alternative treatment for this type of pathology and generating some recommendations for using the Factor.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494861 | PMC |
http://dx.doi.org/10.2147/VHRM.S417447 | DOI Listing |
BMC Med Imaging
July 2025
Department of Radiology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Objective: To develop and evaluate a intralesional and perilesional radiomics strategy based on different machine learning model to differentiate International Society of Urological Pathology (ISUP) grade > 2 group and ISUP ≤ 2 prostate cancers (PCa).
Methods: 340 case of PCa patients confirmed by radical prostatectomy pathology were obtained from two hospitals. The patients were divided into training, internal validation, and external validation groups.
BMC Med Imaging
July 2025
Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: To develop and validate a diagnostic framework integrating intralesional (ILN) and perilesional (PLN) radiomics derived from multiparametric MRI (mpMRI) for distinguishing IgG4-related ophthalmic disease (IgG4-ROD) from orbital mucosa-associated lymphoid tissue (MALT) lymphoma.
Methods: This multicenter retrospective study analyzed 214 histopathologically confirmed cases (68 IgG4-ROD, 146 MALT lymphoma) from two institutions (2019-2024). A LASSO-SVM classifier was optimized through comparative evaluation of seven machine learning models, incorporating fused radiomic features (1,197 features) from ILN/PLN regions.
J Ultrasound Med
June 2025
Department of Dermatology, University of Pisa, Pisa, Italy.
Objectives: Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting hair follicles, significantly impacting patients' quality of life. While clinical assessment remains the cornerstone of diagnosis and staging, ultrasound (US) has emerged as a valuable tool for disease evaluation, treatment guidance, and monitoring. The introduction of ultra-high frequency ultrasound (UHFUS) allowed for near in vivo histopathological examination of HS lesions.
View Article and Find Full Text PDFAbdom Radiol (NY)
June 2025
University of Calgary, Calgary, Canada.
Background And Purpose: To appraise the inclusion of CEUS resection site evaluation in LI-RADS CEUS Nonradiation Treatment Response Assessment (TRA) v2024, currently applied for ablative therapy. We highlight the specific benefits afforded by CEUS in this effort.
Methods: Retrospective chart review was performed for 102 patients following surgical resection of HCC and ICC with post-operative CEUS at our center.
Ultrasound Med Biol
August 2025
Department of Ultrasound, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China; Department Allgemeine Innere Medizin, Kliniken Hirslanden, Beau Site, Salem and Permanence, Bern, Switzerland. Electronic address:
Objective: To evaluate the performance of Liver Imaging Reporting and Data System (LI-RADS) contrast-enhanced ultrasound (CEUS) Nonradiation treatment response assessment (TRA) categorization v2024 for detecting viable tumors of ablated hepatocellular carcinoma (HCC).
Methods: Between June 2020 and December 2022, standardized CEUS data of HCC patients were prospectively collected. A retrospective analysis of LI-RADS CEUS Nonradiation TRA v2024 evaluation on HCCs was conducted by 2 independent radiologists assigning per-lesion TRA (TR-nonviable, TR-equivocal, or TR-viable) categorizations.